Table 3 Summary of T-MPs served as delivery systems for tumor treatment
From: Application of tumor microparticles in tumor prevention and treatment
Cargo carried by T-MPs | Tumor models | Achievements | References |
|---|---|---|---|
Flu | s.c. LLC | Inhibited tumor growth | (Chen et al. 2022) |
MTX | H22 ascites | Reduction in ascites | (Tang et al. 2012) |
Cis | i.p. A2780 | Inhibited tumor growth | (Tang et al. 2012) |
DOX | s.c. H22 /metastatic B16 | Inhibited tumor growth/tumor lung metastasis | (Liang et al. 2019) |
5-FU | s.c. H22 | Inhibited tumor growth | (Liang et al. 2019) |
Bi2Se3 + DOX | s.c. H22 | Inhibited tumor growth | (Wang et al. 2020) |
NAP | s.c. CT26 | Inhibited tumor growth and liver metastasis | (Jing et al. 2023) |
YM155 + MTX | s.c. Saos-2 | Inhibited tumor growth | (Wei et al. 2021a) |
PTX + Bcl-2 siRNA | s.c. MDA-MB-231 | Inhibited tumor growth | (Zhu et al. 2017) |
OAs | s.c. A549/i.p. A549, A2780, CMT64 | Inhibited tumor growth | (Ran et al. 2016) |
MC DNA | 4T1 in situ tumor | Inhibited tumor growth | (Kanada et al. 2019) |
Fe3O4 | s.c. B16, CT26 | Inhibited tumor growth | (Zhao et al. 2019) |